GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longeveron Inc (NAS:LGVN) » Definitions » EPS (Diluted)

Longeveron (Longeveron) EPS (Diluted) : $-9.61 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Longeveron EPS (Diluted)?

Longeveron's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-1.61. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.61.

Longeveron's EPS (Basic) for the three months ended in Mar. 2024 was $-1.61. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.61.

Longeveron's EPS without NRI for the three months ended in Mar. 2024 was $-1.61. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.60.

During the past 3 years, the average EPS without NRIGrowth Rate was -66.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was -32.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Longeveron's highest 3-Year average EPS without NRI Growth Rate was -31.80% per year. The lowest was -66.50% per year. And the median was -53.10% per year.


Longeveron EPS (Diluted) Historical Data

The historical data trend for Longeveron's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longeveron EPS (Diluted) Chart

Longeveron Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial -2.32 -2.21 -9.00 -9.00 -10.20

Longeveron Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.21 -2.70 -2.80 -2.50 -1.61

Competitive Comparison of Longeveron's EPS (Diluted)

For the Biotechnology subindustry, Longeveron's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longeveron's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longeveron's PE Ratio distribution charts can be found below:

* The bar in red indicates where Longeveron's PE Ratio falls into.



Longeveron EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Longeveron's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-21.413-0)/2.173
=-9.85

Longeveron's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-4.058-0)/2.514
=-1.61

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Longeveron  (NAS:LGVN) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Longeveron EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Longeveron's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Longeveron (Longeveron) Business Description

Traded in Other Exchanges
N/A
Address
1951 NW 7th Avenue, Suite 520, Miami, FL, USA, 33136
Longeveron Inc is a clinical-stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company operates out of its leased facilities in Miami, Florida. The company has generated revenue from three sources: 1) Grant awards. 2) The Bahamas Registry Trial. 3) Contract development and manufacturing services.
Executives
Cathy Ross director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Khoso Baluch director 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Jeffrey Pfeffer director
Lisa Locklear officer: Chief Financial Officer 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Nataliya Agafonova officer: Chief Medical Officer 1951 NW 7TH AVENUE, MIAMI FL 33136
James Clavijo officer: CFO and Treasurer 1691 MICHIGAN AVE SUITE 435, MIAMI FL 33139
Hashad Mohamed Wa'el Ahmed officer: Chief Executive Officer SUITE 520, 1951 NW 7TH AVE., MIAMI FL 33136
Joshua Hare director, officer: Chief Scientific Officer C/O 470 NAUTILUS STREET, SUITE 300, LA JOLLA CA 92073
Rock Soffer director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Kwan-hong Christopher Min officer: Chief Medical Officer 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Todd C Girolamo director 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Geoff Green officer: CEO 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Paul T Lehr officer: General Counsel, Secretary 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Ursula Ungaro director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Donald M Soffer director, 10 percent owner 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136